StockNews.com Initiates Coverage on Bellicum Pharmaceuticals (NASDAQ:BLCM)

Analysts at StockNews.com started coverage on shares of Bellicum Pharmaceuticals (NASDAQ:BLCM) in a research note issued to investors on Tuesday. The firm set a “sell” rating on the biopharmaceutical company’s stock.

Bellicum Pharmaceuticals Trading Down 6.6 %

NASDAQ:BLCM opened at $0.07 on Tuesday. Bellicum Pharmaceuticals has a one year low of $0.06 and a one year high of $1.31. The company has a fifty day moving average price of $0.08 and a 200 day moving average price of $0.14.

Hedge Funds Weigh In On Bellicum Pharmaceuticals

An institutional investor recently bought a new position in Bellicum Pharmaceuticals stock. HRT Financial LP acquired a new stake in Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor acquired 36,470 shares of the biopharmaceutical company’s stock, valued at approximately $26,000. HRT Financial LP owned approximately 0.42% of Bellicum Pharmaceuticals as of its most recent filing with the SEC. 4.93% of the stock is currently owned by institutional investors.

Bellicum Pharmaceuticals Company Profile

Bellicum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers and solid tumors in the United States and internationally. The company's clinical product candidates include BPX-601, an autologous GoCAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of solid tumors expressing the prostate stem cell antigen.